PDB17 TOTAL Cost of Care and Utilization Among Medicare Fee-for-Service (FFS) Patients with Metastatic Pancreatic Cancer Treated with FDA-Approved/NCCN® Category 1 Regimens at 340B VS. NON-340B Hospitals
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.415
https://www.valueinhealthjournal.com/article/S1098-3015(21)00632-X/fulltext
Title :
PDB17 TOTAL Cost of Care and Utilization Among Medicare Fee-for-Service (FFS) Patients with Metastatic Pancreatic Cancer Treated with FDA-Approved/NCCN® Category 1 Regimens at 340B VS. NON-340B Hospitals
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00632-X&doi=10.1016/j.jval.2021.04.415
First page :
Section Title :
Open access? :
No
Section Order :
10983